Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 11/13/2017
Entire Document
 

Picture 3


 

small lymphocytic lymphoma patients;

o

Global pivotal Phase 2 trial of BGB-3111 in combination with GAZYVA® (obinutuzumab) in relapsed or refractory follicular lymphoma patients; and

o

Pivotal Phase 2 trial in China of BGB-3111 in Waldenström’s macroglobulinemia.

BGB-A317an investigational humanized monoclonal antibody against the immune checkpoint receptor PD-1

·

Presented data from patients with gastric cancer, esophageal cancer, head and neck squamous cell carcinoma, and ovarian cancer enrolled in the global Phase 1 trial of BGB-A317 in patients with advanced solid tumors at the European Society for Medical Oncology (ESMO) 2017 Congress;

·

Presented preliminary Phase 1 data on BGB-A317 in Chinese patients with advanced tumors at the 20th Annual Meeting of the Chinese Society of Clinical Oncology;

·

Completed enrollment in the pivotal Phase 2 trial of BGB-A317 in China in relapsed/refractory classical Hodgkin’s lymphoma;

·

Completed enrollment in the global Phase 1a/1b trial of BGB-A317 in advanced tumors with a total of over 450 patients;  

·

Initiated the following trials:

o

Phase 3 trial in China of BGB-A317 as a  second- or third-line treatment for patients with advanced lung cancer; 

o

Pivotal Phase 2 trial in China of BGB-A317 in previously treated, PD-L1-positive, locally advanced or metastatic urothelial cancer; 

o

Phase 2 trial in China of BGB-A317 in combination with chemotherapy as a  first-line treatment for patients with advanced lung cancer; and

o

Phase 2 trial in China of BGB-A317 in combination with chemotherapy as a first-line treatment for patients with locally

 


 


© 2016 BeiGene. All Rights Reserved.